PRECISIONBIOLOGICS
Menu
↗
Comparisons

Amniotic vs Wharton's jelly: procurement differences

Procurement-focused differences between amniotic and Wharton's jelly products without wound or disease claims.

Reviewed 2026-10-27

Start with labeled identity

Begin with the exact tissue type, presentation, and storage class on the current insert. Catalog names help you find a SKU; they do not replace lot-linked identity.

Independent evaluations of commercial cord-tissue allografts have reported low cell counts and only rare viable stem cells. Precision Biologics does not represent these products as containing functional living stem cells or as stem cell therapies.

Documentation to request and file

Request the current insert, certificate of analysis format, donor eligibility summary approach, sterility testing description, and shipping instructions before the first purchase order.

At receipt, match lot ID, expiration, and shipper condition to the purchase order. Incomplete packs stay open—do not close them by assumption.

Counsel and supervision checkpoints

Physician supervision structures should be documented for account verification. Intended-use questions go to clinic counsel.

Account approval is not authorization for a specific application.

Operational checklist for amniotic vs wharton's jelly procurement

Before ordering under the topic amniotic vs wharton's jelly procurement, confirm storage class, receiving owner, and which documents will be required at release.

Close open items in writing. Do not infer missing COA fields from a different lot or SKU.

FAQ

Frequently asked questions

Is a larger vial stronger?+

Not as a clinical claim. It is a different presentation to verify on the label.

Can we treat similar perinatal tissues as interchangeable?+

No. Confirm tissue type and keep separate files.

What should win a comparison?+

Documentation completeness, logistics fit, and claim discipline—not slogans.

Does this page determine how we may use products discussed under amniotic vs wharton's jelly procurement?+

No. Intended use remains with the ordering physician and clinic counsel.

Sources

  1. FDA: Minimal Manipulation and Homologous Use guidance ↗FDA
  2. 21 CFR Part 1271 ↗eCFR